The regulatory context: why compounding is legal and what constraints apply
Compounded tirzepatide exists within a specific legal window. When the FDA lists a drug as being in shortage, Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed compounding pharmacies to prepare that drug’s active pharmaceutical ingredient (API) for individual patients pursuant to a valid prescription. That window created the market for compounded tirzepatide when Zepbound and Mounjaro supply constraints were formally documented.
This legal window does not suspend all quality requirements. Compounding pharmacies must comply with USP <797> sterile compounding standards, state pharmacy board licensing requirements, and FDA guidance on 503A operations. The legal basis for compounding does not create a license for unverified sourcing or substandard preparation.
The shortage status and associated compounding permissions are subject to change. Patients and providers should monitor FDA communications, as changes in shortage designation affect the legal pathway for compounding.
What is the difference between a 503A and 503B compounding pharmacy?
You will encounter references to both 503A pharmacies and 503B outsourcing facilities in discussions about compounded tirzepatide. The distinction is operationally significant:
| Criterion | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Regulatory body | State pharmacy board | FDA (direct registration) |
| Prescription required | Yes — patient-specific | No — may compound for office stock |
| Volume | Individual patient orders | Bulk batches |
| Primary customers | Individual patients via telehealth | Hospitals, clinics, surgical centers |
| Quality standard | USP <797> sterile compounding | cGMP (FDA-inspected) |
| PepScribe standard | Yes — 503A only | Not used for patient prescriptions |
For individual patients receiving tirzepatide through a telehealth prescription, the relevant standard is 503A. A compound prepared by a licensed 503A pharmacy for your specific prescription is the appropriate model. PepScribe partners exclusively with 503A pharmacies.
A provider unwilling to name its pharmacy, its API source, or its sterility testing should not be trusted with an injectable.
What separates a quality tirzepatide compounding pharmacy from a low-quality one?
API sourcing transparency
The active pharmaceutical ingredient in compounded tirzepatide must come from an FDA-registered supplier with verified purity. Overseas API, particularly from unverified sources, introduces unknown impurities, inaccurate concentrations, and supply-chain opacity. The safest supply chains are domestic, with traceable documentation.
Ask explicitly: where is the API sourced, and can you provide supplier documentation? A provider unwilling or unable to answer this question should not be trusted with a controlled-dose injectable.
Independent certificate of analysis testing
A certificate of analysis (CoA) documents the results of third-party laboratory testing for potency, sterility, and endotoxins. In-house testing from the same pharmacy that prepared the compound is a weaker quality signal than testing by an independent accredited laboratory. Ask whether third-party CoA testing is performed on each production batch.
For a compound injected subcutaneously once per week, sterility is not optional. The USP <797> standards for sterile compounding represent the minimum; independent testing is best practice.
State licensing and PCAB accreditation
Verify that the compounding pharmacy is licensed in your state or holds a non-resident pharmacy license valid in your state. Most state pharmacy boards maintain publicly searchable license databases. Pharmacy Compounding Accreditation Board (PCAB) accreditation is a voluntary additional credential that signals the pharmacy has undergone independent quality evaluation beyond the minimum licensing requirements.
Transparent fill and labeling
Compounded tirzepatide should be labeled with: the exact concentration (mg/mL), total volume, lot number, beyond-use date, prescribing clinician name, and patient name. Vials lacking clear labeling or missing batch information are a quality concern.
The clinician side of the equation
The pharmacy is only half the picture. The clinician prescribing tirzepatide must be licensed in your state, must conduct a proper medical evaluation before prescribing, and should remain available for follow-up as you titrate through doses.
Tirzepatide has absolute contraindications: personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 (MEN2). Pancreatitis history warrants clinical discussion. These are not screening questions that can be self-administered through a checkbox form.
Ongoing dose titration guidance — from 2.5 mg through 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg — benefits from clinical monitoring of side effects and weight trend. A quality telehealth provider includes structured follow-up, not just prescription refills.
How PepScribe handles pharmacy selection
PepScribe prescribes tirzepatide through licensed 503A pharmacies with US-based API sourcing and independent potency and sterility testing. The clinician review process screens for contraindications and establishes a dosing plan before any prescription is issued. Patients have access to ongoing support through their program.
We do not use 503B facilities for individual patient prescriptions. We do not use overseas API sources. The supply chain behind every tirzepatide prescription we support is disclosed, not obscured.
If you want to see the program in detail, including what the clinical process and pricing look like, the tirzepatide program page covers it.
Frequently asked questions
What makes a tirzepatide compounding pharmacy legitimate?
A legitimate compounding pharmacy for tirzepatide must be licensed as a 503A pharmacy under state board oversight, compound only pursuant to a valid patient-specific prescription, source API from FDA-registered suppliers, and meet USP compounding standards for sterile preparations. Independent certificate of analysis (CoA) testing for potency and sterility is an additional quality marker.
Can I get tirzepatide online from a compounding pharmacy?
Yes — through a telehealth provider that connects you with a licensed clinician. The clinician evaluates your candidacy and, if appropriate, issues a prescription to a licensed 503A compounding pharmacy that ships to your state. You cannot legally obtain compounded tirzepatide without a valid prescription.
How do I verify a tirzepatide compounding pharmacy is legitimate?
Check the pharmacy's state license status via your state pharmacy board database, look for PCAB accreditation as an additional voluntary quality marker, ask whether the pharmacy performs independent CoA testing (not just in-house testing), and confirm the API sourcing chain. Reputable telehealth platforms disclose their pharmacy partners.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
Compounded tirzepatide contains tirzepatide as the active pharmaceutical ingredient but is not FDA-approved as a finished drug product. Branded Zepbound and Mounjaro went through the full FDA drug approval process; compounded products have not. Quality 503A pharmacies conduct their own testing, but the regulatory bar is different.
What is the difference between a 503A and 503B compounding pharmacy?
503A pharmacies compound patient-specific medications pursuant to individual prescriptions and are regulated primarily by state pharmacy boards. 503B outsourcing facilities compound larger batches for office stock without patient-specific prescriptions and are registered with the FDA. PepScribe uses 503A pharmacies exclusively.
What should I ask a telehealth provider about their compounding pharmacy?
Ask: What 503A pharmacy compounds the tirzepatide? Is the pharmacy licensed in my state? Where is the API sourced — domestic or overseas? Does the pharmacy provide independent CoA testing? What sterility testing protocols are used? Is the prescribing clinician licensed in my state?